MOR News and Press, MorphoSys AG From 03/17/22

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q4 2021 Earnings Call Mar 17, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q4 2021 Earnings Call Transcript

– Monjuvi ® U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021 – Pipeline advances: enrollment progressing across three Phase 3 trials in myelofibr...

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network (R) (NCCN) Clinical Practice Guidelines (NCCN Guidelines (R) ) in Oncology for B-cell Lymphomas have...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT). MorphoSys' Management team will host a conference call...

German biotech, MorphoSys AG (MOR -2.8%) announced on Thursday that the company would report €231M worth of non-cash impairment charge on goodwill after the consolidation of its R&D activities following the acquisition of Constellation Pharmaceuticals last year. The move followed a...

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) announces today that it will account for a non-cash impairment charge on goodwill in th...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European healthcare companies for female...

Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 18, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR)...

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. E...